Mark Sands

Company: WUSTL

Job title: Professor

Bio:

 

Seminars:

Panel Discussion: Assessing the Risk of Insertional Mutagenesis by AAV Gene Therapies 5:45 pm

This panel will be a structured conversation designed to answer key questions such as: What is the rate of integration of AAV vectors? What is the structure of the integrated viral sequences? Is the risk dependent on dose? What is the role of species differences when looking at preclinical data, will this translate to humans?…Read more

day: Day One

AAV-Associated Hepatocellular Carcinoma 4:45 pm

High dose systemic AAV administration in newborn mice is associated with an increased incidence of HCC AAV-associated HCC is a protracted phenotype AAV administration combined with other treatments that may have some oncogenic potential greatly increases the incidence of HCCRead more

day: Day One